Trial Profile
A Phase 1, Open-Label, Single Dose Study to Evaluate the Safety and Efficacy of Nivolumab With or Without GS 4774 for the Treatment of Virally Suppressed Subjects with Chronic Hepatitis B
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs GS 4774 (Primary) ; Nivolumab (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 12 Jul 2019 Results published in the Journal of Hepatology
- 30 Jan 2017 Status changed from recruiting to completed.
- 17 Jun 2016 New trial record